FogPharma Strengthens New Modality Drug Hunting Team with Appointment of Howard Stern as Chief Scientific Officer and Peter Fekkes as Vice President of Discovery Bioscience
BOSTON, May 6, 2019 /PRNewswire/ -- FogPharma today announced the appointment of Howard Stern, M.D., Ph.D., as Chief Scientific Officer.
- BOSTON, May 6, 2019 /PRNewswire/ -- FogPharma today announced the appointment of Howard Stern, M.D., Ph.D., as Chief Scientific Officer.
- In addition, FogPharma also announced the appointment of Peter Fekkes, Ph.D., as Vice President of Discovery Bioscience.
- The addition of Howard and Peter to our team represents a quantum leap forward for FogPharma as a mature, powerful and effective new modality drug discovery organization."
- "I'm pleased to join the FogPharma team at a time when pioneering new discovery and development approaches are increasingly important to combat intracellular disease drivers," said Dr. Stern.